Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo

Incyte announced the validation of the European Marketing Authorization Application for ruxolitinib cream, a topical JAK inhibitor, as a potential treatment for adolescents and adults with non-segmental vitiligo with facial involvement.